{"product_id":"edsa-vrio-analysis","title":"Edesa Biotech, Inc. (EDSA): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Edesa Biotech, Inc. (EDSA)'s market staying power with this concise VRIO Analysis. We cut straight to the chase, evaluating whether its core assets truly deliver sustainable competitive advantage by scrutinizing their Value, Rarity, Inimitability, and Organization. Read on to see the distilled summary of its strategic position and what it means for its future success.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEdesa Biotech, Inc. (EDSA) - VRIO Analysis: EB06 (Anti-CXCL10 mAb) Vitiligo Program Advancement\n\u003c\/h2\u003e\n\n\u003cp\u003eYou're looking at Edesa Biotech, Inc.'s EB06 program, and the key takeaway right now is that the company has made a sharp pivot to focus on this anti-CXCL10 monoclonal antibody for vitiligo, aiming for a major regulatory milestone by the end of this year. This focused effort is what we'll assess through the VRIO lens.\u003c\/p\u003e\n\n\u003cp\u003eHere is the quick math on the current state of play for EB06:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n    \u003ctd\u003eAssessment\u003c\/td\u003e\n    \u003ctd\u003eKey Supporting Data (2025 Fiscal)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eHigh\u003c\/td\u003e\n    \u003ctd\u003eTargeting moderate-to-severe nonsegmental vitiligo in a market valued at \u003cstrong\u003e$1.60 billion\u003c\/strong\u003e in 2025.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eModerate\u003c\/td\u003e\n    \u003ctd\u003eAnti-CXCL10 mechanism is less common than the recently approved JAK inhibitors like ruxolitinib.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003eModerate\u003c\/td\u003e\n    \u003ctd\u003eSpecific antibody construct and the clinical data package are not instantly replicable.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eHigh\u003c\/td\u003e\n    \u003ctd\u003eManagement has clearly refocused resources, maintaining \u003cstrong\u003e$12.4 million\u003c\/strong\u003e in cash to hit the end-of-2025 IND target.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n    \u003ctd\u003eTemporary\u003c\/td\u003e\n    \u003ctd\u003eAdvantage is entirely contingent on successful IND acceptance and execution of the upcoming Phase 2 trial.\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eValue: Addressing a Major Unmet Need\u003c\/h\u003e\n\u003cp\u003eEB06 directly targets a high unmet need in vitiligo, which is an autoimmune condition causing skin depigmentation. The market itself is substantial; we saw the global vitiligo treatment market valued at around \u003cstrong\u003e$1.60 billion\u003c\/strong\u003e in 2025. That’s a big prize. Non-segmental vitiligo, the target indication, is the most common form, accounting for about \u003cstrong\u003e65.51%\u003c\/strong\u003e of the market share in 2024. A novel, targeted immunotherapy that can restore pigmentation is definitely valuable here, especially since existing treatments have limitations.\u003c\/p\u003e\n\n\u003ch\u003eRarity: A Different Mechanism of Attack\u003c\/h\u003e\n\u003cp\u003eWhat makes EB06 rare right now is its mechanism. The FDA has approved topical JAK inhibitors, like ruxolitinib cream, which is a big deal. However, EB06 is an anti-CXCL10 monoclonal antibody. The chemokine CXCL10 has been shown to be elevated in vitiligo patient skin and serum, suggesting it plays a key role in the disease process. While other biologics are in the pipeline - think Incyte’s Povorcitinib or AbbVie’s RINVOQ - the specific CXCL10 pathway blockade offers a differentiated approach that isn't widely available yet.\u003c\/p\u003e\n\n\u003ch\u003eImitability: The Data Moat\u003c\/h\u003e\n\u003cp\u003eHonestly, the antibody itself is hard to copy quickly, but the real barrier to imitation is the data package Edesa is building. It takes years and millions of dollars to generate the manufacturing data needed for an Investigational New Drug (IND) application. Edesa is planning to submit this manufacturing data to the FDA by the \u003cstrong\u003eend of 2025\u003c\/strong\u003e. If they get that IND accepted, the clinical data supporting the mechanism in humans becomes the hard-to-replicate asset. Until then, competitors are likely working on similar targets, making the advantage only moderately protected.\u003c\/p\u003e\n\n\u003ch\u003eOrganization: Focused Execution\u003c\/h\u003e\n\u003cp\u003eThe organization seems to be putting its chips on the table with EB06. They reported a net loss of \u003cstrong\u003e$1.7 million\u003c\/strong\u003e for Q3 2025, with operating expenses at \u003cstrong\u003e$1.9 million\u003c\/strong\u003e for that quarter. Crucially, management has stated their existing cash, which stood at \u003cstrong\u003e$12.4 million\u003c\/strong\u003e as of June 30, 2025, plus grants, should fund the vitiligo program through the \u003cstrong\u003eend of fiscal 2026\u003c\/strong\u003e. This focused resource allocation toward the IND submission target shows they are organized to execute this near-term goal.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage: The Next Hurdle\u003c\/h\u003e\n\u003cp\u003eThe current advantage is \u003cstrong\u003etemporary\u003c\/strong\u003e. It exists because they are on the cusp of a major regulatory step that others might not have reached yet. The advantage hinges entirely on two things: first, the FDA accepting their IND application, which they aim for by the close of 2025, and second, successfully executing the subsequent Phase 2 study. If they clear the IND hurdle, they secure a first-mover advantage in the CXCL10 space, but that clock starts ticking immediately upon acceptance.\u003c\/p\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEdesa Biotech, Inc. (EDSA) - VRIO Analysis: EB01 (Daniluromer Cream) Phase 3-Ready Asset\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eEB01 (Daniluromer Cream) Phase 3-Ready Asset\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a near-term, non-systemic treatment option for chronic Allergic Contact Dermatitis (ACD). The asset demonstrated statistically significant efficacy in its Phase 2b trial.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eEfficacy Metric (1.0% EB01 vs. Placebo at Day 29)\u003c\/th\u003e\n\u003cth\u003e1.0% EB01 Improvement\u003c\/th\u003e\n\u003cth\u003ePlacebo Improvement\u003c\/th\u003e\n\u003cth\u003eP-Value\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eContact Dermatitis Severity Index (CDSI) Average Improvement (Primary Endpoint)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e60%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e39%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.02\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInvestigator's Static Global Assessment (ISGA) - Clear\/Almost Clear\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e53%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e29%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.04\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBody Surface Area (BSA) Reduction\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e42.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.054\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePruritis\/Itching Improvement\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e60.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e41.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.06\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe 1.0% EB01 cream also showed a 62.9% reduction in dryness versus 35.9% for placebo ($\\text{P}=0.02$) and a 63.1% reduction in fissures versus 44.3% for placebo ($\\text{P}=0.02$).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; many companies have topical assets, but being Phase 3-ready is a strong position. The asset is based on an sPLA2 inhibitor mechanism for ACD.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; the formulation and Phase 3 package could be replicated with time and capital. The positive Phase 2b results provide a clear data package for replication\/development by a partner.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; the company is currently prioritizing EB06, meaning EB01 development is on the back burner, with the company in 'active partnering discussions to advance that program into late stage trials.'\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eResearch and development expenses for the nine months ended June 30, 2025 were $2.4 million, with R\u0026amp;D expenses for the three months ended June 30, 2025 at $0.9 million.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D expenses showed an increase related to EB06 for the planned Phase 2 vitiligo study, while expenses related to the respiratory drug EB05 decreased.\u003c\/li\u003e\n\u003cli\u003eAs of June 30, 2025, Edesa had cash and cash equivalents of $12.4 million and reported a net loss of $5.0 million for the nine months ended June 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; it’s a valuable asset for a potential partnership or future development, but not currently driving core focus.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEdesa Biotech, Inc. (EDSA) - VRIO Analysis: EB05 (Paridiprubart) Host-Directed Therapeutic (HDT) Platform\n\u003c\/h2\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eRepresents a novel class of therapeutics modulating the immune response, applicable across various acute\/chronic conditions like ARDS. EB05 (Paridiprubart) demonstrated statistically significant and clinically meaningful benefits in a Phase 3 study for ARDS in patients on invasive mechanical ventilation (IMV) with a positive SARS-CoV-2 test. The platform inhibits toll-like receptor 4 (TLR4). Approximately 10% of all intensive care admissions are ARDS related.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eEndpoint (vs. Placebo + SOC)\u003c\/th\u003e\n\u003cth\u003eEB05 + SOC Result\u003c\/th\u003e\n\u003cth\u003eStatistical Significance\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e28-Day Mortality (ITT Population)\u003c\/td\u003e\n\u003ctd\u003e39% vs 52% (Absolute survival improvement of 13%)\u003c\/td\u003e\n\u003ctd\u003eRelative risk reduction of 25% ($p\u0026lt;0.001$)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e60-Day Mortality (ITT Population)\u003c\/td\u003e\n\u003ctd\u003e46% vs 59% (Absolute survival improvement of 13%)\u003c\/td\u003e\n\u003ctd\u003eRelative risk reduction of 22% ($p=0.003$)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Improvement at Day 28 (No longer requiring IMV\/organ support)\u003c\/td\u003e\n\u003ctd\u003e41% higher relative rate\u003c\/td\u003e\n\u003ctd\u003eNot explicitly stated for this metric, but related to WHO scale improvement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWHO COVID-19 Severity Scale $\\ge 2$ point improvement at Day 28\u003c\/td\u003e\n\u003ctd\u003e38% vs 27%\u003c\/td\u003e\n\u003ctd\u003e($p=0.032$)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe Phase 3 trial enrolled 104 adult patients from 38 hospitals. Safety data exists from more than 275 subjects.\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eHigh; HDTs are a specialized, less crowded therapeutic area compared to direct pathogen targeting. The development of EB05 is currently being evaluated in a $117M platform study funded by BARDA.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eHigh; the underlying science and data from prior trials are difficult for competitors to replicate. The Phase 2 substudy demonstrated an 84% reduction in the risk of dying at 28 days compared to placebo plus standard of care in a critically ill substudy population.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eHigh; the platform underpins the company’s entire scientific thesis and R\u0026amp;D direction. The development of EB05 is fully funded by the U.S. government in the BARDA platform trial, with a primary completion date listed as November 2027. As of June 30, 2025, Edesa had $12.4 million in cash and cash equivalents. Total assets were $14.80M as of Q3 2025.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal liabilities as of the fiscal quarter ending June 30, 2025: $672.67K.\u003c\/li\u003e\n\u003cli\u003eNet loss for the nine months ended June 30, 2025: $5.0 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eSustained; the platform technology itself offers a long-term strategic asset. The Phase 3 results showed a durable survival benefit at 60 days with a 22% relative risk reduction in the risk of death.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEdesa Biotech, Inc. (EDSA) - VRIO Analysis: U.S. Government Funding for EB05 (ARDS Study)\n\u003c\/h2\u003e\n\n\u003cp\u003eThe U.S. Government funding via BARDA for the EB05 (paridiprubart) ARDS study provides a tangible, non-dilutive validation of the Host-Directed Therapeutic (HDT) approach.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eValue: De-risks a significant portion of EB05 development costs and validates the HDT approach via a U.S. government-funded platform study.\u003c\/h\u003e\n\u003cp\u003eThe selection by the Biomedical Advanced Research and Development Authority (BARDA) for a U.S. government-funded clinical study validates the technology platform.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\/Value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrevious Phase 2 Mortality Reduction (ARDS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e84%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 Trial Enrollment Target\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e600\u003c\/strong\u003e subjects\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 Primary Endpoint (28-Day Mortality) Absolute Improvement\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 Primary Endpoint (28-Day Mortality) Relative Reduction\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBARDA-Funded Study Phase\u003c\/td\u003e\n\u003ctd\u003ePhase 2 Platform Study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBARDA-Funded Study Estimated Value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$117M\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003e\u003ch\u003eRarity: High; securing non-dilutive, government-backed clinical trial funding is rare for smaller biotechs.\u003c\/h\u003e\n\u003cp\u003eSecuring this level of government support for a clinical trial is a rare event, particularly for a company with a market capitalization of \u003cstrong\u003e$18.5 million\u003c\/strong\u003e as of October 28, 2025.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGovernment of Canada Strategic Innovation Fund (SIF) commitment for Phase 3: Up to \u003cstrong\u003eCAD$23 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFY2024 Net Loss: \u003cstrong\u003e$6.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFY2024 Total Operating Expenses Reduction: \u003cstrong\u003e$2.2 million\u003c\/strong\u003e (from $9.2 million to \u003cstrong\u003e$7.0 million\u003c\/strong\u003e).\u003c\/li\u003e\n\u003cli\u003ePost-Fiscal Year Funding Secured: \u003cstrong\u003e$2.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eImitability: High; the specific award and partnership terms are unique to Edesa Biotech.\u003c\/h\u003e\n\u003cp\u003eThe specific terms of the BARDA contract and the selection following a competitive review process are proprietary and non-replicable by competitors.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe BARDA study evaluates \u003cstrong\u003ethree\u003c\/strong\u003e novel Host-Directed Therapeutics (HDTs).\u003c\/li\u003e\n\u003cli\u003eThe Canadian SIF funding supports Phase 3 study expenses, including hospital\/physician expenditures and scale-up manufacturing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization: High; the company benefits from the study's structure, allowing them to focus capital elsewhere.\u003c\/h\u003e\n\u003cp\u003eThe structure of the funding arrangement allows Edesa to leverage external resources for the BARDA-funded trial.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eResource Allocation Area\u003c\/td\u003e\n\u003ctd\u003eFunding Source\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBARDA Phase 2 Study Costs\u003c\/td\u003e\n\u003ctd\u003eU.S. Government (BARDA)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 Trial Expenses (Partial)\u003c\/td\u003e\n\u003ctd\u003eGovernment of Canada (SIF)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 Manufacturing Scale-up\u003c\/td\u003e\n\u003ctd\u003eGovernment of Canada (SIF)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 R\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage: Temporary; the advantage lasts as long as the fully funded study is active and beneficial.\u003c\/h\u003e\n\u003cp\u003eThe advantage is tied to the execution and positive data generation from the government-supported study, which is designed to support approval for all-cause ARDS.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe BARDA study focuses on ARDS due to a \u003cstrong\u003evariety of causes\u003c\/strong\u003e, broadening data beyond the Phase 3 SARS-CoV-2 focus.\u003c\/li\u003e\n\u003cli\u003eThe primary endpoint for the BARDA Phase 2 trial cohort is the mortality rate at \u003cstrong\u003e28 days\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eEdesa Biotech, Inc. (EDSA) - VRIO Analysis: Cash Position and Recent Financing Strength (as of June 30, 2025)\n\u003c\/h2\u003e\n\n\u003cp\u003eThe analysis below is based on financial data reported as of the end of the third fiscal quarter, June 30, 2025.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe cash position provides the necessary runway to execute the critical EB06 IND submission planned by the end of calendar 2025 and initial Phase 2 preparation. The balance sheet strength is further supported by a capital structure with \u003cstrong\u003ezero total debt to equity\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and cash equivalents as of June 30, 2025: \u003cstrong\u003e$12.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eWorking capital as of June 30, 2025: \u003cstrong\u003e$12.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eManagement expectation: Existing cash plus grants to fund the EB06 vitiligo program through the \u003cstrong\u003eend of fiscal 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eLow; the cash level is typical for a clinical-stage biotech, though the recent financing provided a temporary buffer against the burn rate.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRecent Equity Financing: \u003cstrong\u003e$15.0 million\u003c\/strong\u003e gross proceeds secured prior to this reporting period [cite: 1, 2 from previous search].\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eHigh; the capital structure, including the recent financing and observable cash balance, is easily observable and replicable through public and private equity markets.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eModerate; the recent \u003cstrong\u003e$15 million\u003c\/strong\u003e financing helped stabilize operations, but the continued operating losses indicate cash burn persists, necessitating continued access to capital markets or grant funding.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric (Nine Months Ended June 30, 2025)\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (Prior Year Period)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Operating Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eTemporary; the current cash position is a necessary resource for near-term milestones (EB06 IND submission by end of 2025), not a sustainable competitive advantage unless it significantly outlasts peers requiring capital raises.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEdesa Biotech, Inc. (EDSA) - VRIO Analysis: Intellectual Property on Novel Monoclonal Antibodies (mAbs)\n\u003c\/h2\u003e\n\n\u003ch\u003eIntellectual Property on Novel Monoclonal Antibodies (mAbs)\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Protects the specific mechanisms of action for EB06 (anti-CXCL10) and the underlying HDT approach.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; patents are standard, but the breadth across multiple targets (CXCL10, TLR4) is valuable.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; competitors can design around patents, but infringement risk remains.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; the IP portfolio needs active defense, which requires legal resources.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; patents provide a legal barrier to entry for specific molecules.\u003c\/p\u003e\n\n\u003cp\u003eThe company secured an exclusive license agreement in April 2020 for know-how, patents, and data relating to monoclonal antibodies targeting TLR4 and CXCL10.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\/Target\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Status\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFiscal Year 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost-Fiscal Year Funding Secured\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAfter September 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEB06 IND Submission Target (FDA)\u003c\/td\u003e\n\u003ctd\u003eMid-2025\u003c\/td\u003e\n\u003ctd\u003ePlanned\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEB06 Topline Readout Post-Clearance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12 to 18 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAnticipated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eInvestment in R\u0026amp;D, which supports the IP, was:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eResearch and development expenses were \u003cstrong\u003e$2.9 million\u003c\/strong\u003e for the fiscal year ended September 30, 2024.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses were \u003cstrong\u003e$0.9 million\u003c\/strong\u003e for the three months ended June 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe company's financial position as of September 30, 2024, included:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet loss of \u003cstrong\u003e$6.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNegative working capital of \u003cstrong\u003e$0.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eEdesa Biotech, Inc. (EDSA) - VRIO Analysis: Canadian Government Strategic Innovation Fund Relationship\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe relationship provided non-dilutive funding for the EB05 program, offsetting R\u0026amp;D expenses for that asset. The commitment was up to \u003cstrong\u003eC$23 million\u003c\/strong\u003e from the Government of Canada under the Strategic Innovation Fund (SIF) to support the \u003cstrong\u003e$61 million\u003c\/strong\u003e EB05 Phase III clinical trial project, announced on \u003cstrong\u003eOctober 12, 2023\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFunding Event\u003c\/th\u003e\n\u003cth\u003eDate\u003c\/th\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial SIF\/SRF Funding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eFebruary 2, 2021\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEB05 Development\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$14 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSecond SIF Funding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOctober 12, 2023\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEB05 Phase III Clinical Trial\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003eC$23 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGovernment grants are common, but securing multiple distinct awards for the same asset from the SIF\/SRF is less common.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe initial award was up to \u003cstrong\u003e$14 million\u003c\/strong\u003e on \u003cstrong\u003eFebruary 2, 2021\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe subsequent award was up to \u003cstrong\u003eC$23 million\u003c\/strong\u003e on \u003cstrong\u003eOctober 12, 2023\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe specific relationship and past awards are company-specific history, established through a competitive review process.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWhile funding decreased in the first nine months of 2025, the relationship's impact is documented in financial reporting and employment figures.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe \u003cstrong\u003e$23 million\u003c\/strong\u003e contribution supports the creation of \u003cstrong\u003e34 new positions\u003c\/strong\u003e and maintenance of the existing workforce.\u003c\/li\u003e\n\u003cli\u003eTotal other income decreased by \u003cstrong\u003e$0.3 million\u003c\/strong\u003e to \u003cstrong\u003e$0.5 million\u003c\/strong\u003e for the nine months ended \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e, compared to \u003cstrong\u003e$0.8 million\u003c\/strong\u003e for the same period last year, primarily due to a decrease in reimbursement funding from the SIF.\u003c\/li\u003e\n\u003cli\u003eFor the three months ended \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e, other income decreased by \u003cstrong\u003e$110,000\u003c\/strong\u003e to \u003cstrong\u003e$154,000\u003c\/strong\u003e compared to the same period in the prior year.\u003c\/li\u003e\n\u003cli\u003eFor the six months ended \u003cstrong\u003eMarch 31, 2025\u003c\/strong\u003e, other income decreased by \u003cstrong\u003e$208,000\u003c\/strong\u003e to \u003cstrong\u003e$331,000\u003c\/strong\u003e compared to the same period in 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary; the benefit is realized through past cost savings, but future funding isn't guaranteed.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eResearch and development expenses decreased by \u003cstrong\u003e$0.4 million\u003c\/strong\u003e to \u003cstrong\u003e$2.4 million\u003c\/strong\u003e for the nine months ended \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e compared to the same period in 2024, partially due to decreased external research expenses related to EB05.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eEdesa Biotech, Inc. (EDSA) - VRIO Analysis: Clinical Development Expertise in Host-Directed Therapeutics\n\u003c\/h2\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eExpertise supports the development of novel HDTs like EB05 (paridiprubart), an anti-TLR4 drug candidate, which demonstrated efficacy in a Phase 3 study for Acute Respiratory Distress Syndrome (ARDS).\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eEB05 + SoC\u003c\/th\u003e\n\u003cth\u003ePlacebo + SoC\u003c\/th\u003e\n\u003cth\u003eAbsolute Improvement\u003c\/th\u003e\n\u003cth\u003eRelative Reduction\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e28-Day Mortality\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e39%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e52%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e60-Day Mortality\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e46%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e59%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e22%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePopulation ($n$)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e104\u003c\/strong\u003e (ITT)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e104\u003c\/strong\u003e (ITT)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe same asset, EB05, is being evaluated in a U.S. government-funded Phase 2 platform study of HDTs.\u003c\/p\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eFocused experience in the HDT modality is rare, evidenced by securing government funding for the EB05 program from the U.S. government and the Government of Canada.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe company is advancing EB06 (anti-CXCL10) for vitiligo, with an anticipated FDA submission by the end of \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eEB06 has received regulatory approval from Health Canada to initiate a Phase 2 study.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eTacit knowledge is embedded in the team's ability to secure and manage government-funded studies, such as the fully funded U.S. government study for EB05.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe company reported a net loss of \u003cstrong\u003e$1.7 million\u003c\/strong\u003e for the quarter ended June 30, 2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses for the nine months ended June 30, 2025, were \u003cstrong\u003e$2.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eOperational efficiency is suggested by the strategic pivot to prioritize EB06 development while benefiting from the fully funded EB05 study.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe company completed a \u003cstrong\u003e$15 million\u003c\/strong\u003e equity financing to support EB06 development.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents were \u003cstrong\u003e$12.4 million\u003c\/strong\u003e at June 30, 2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eWorking capital was \u003cstrong\u003e$12.1 million\u003c\/strong\u003e at June 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eThe sustained advantage is derived from the validated TLR4 technology, which secured a third competitive government award.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eFor Fiscal Year 2024, total operating expenses were \u003cstrong\u003e$16.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eFY 2024 R\u0026amp;D expenses were \u003cstrong\u003e$2.9 million\u003c\/strong\u003e, a decrease from \u003cstrong\u003e$4.8 million\u003c\/strong\u003e in the prior year.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eEdesa Biotech, Inc. (EDSA) - VRIO Analysis: Strategic Refocusing on EB06 for Vitiligo\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Concentrates limited capital and management attention on the most promising near-term regulatory milestone (IND submission by end of 2025). The IND submission target for EB06 shifted to the \u003cstrong\u003esecond half of calendar 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; pivoting focus is a common, if difficult, executive decision.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; competitors can copy the strategy, but execution is internal.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the Q2 2025 results showed decreased EB05 expenses offsetting EB06 increases, showing organizational alignment. Total operating expenses for the three months ended March 31, 2025 were \u003cstrong\u003e$1.6 million\u003c\/strong\u003e, compared to \u003cstrong\u003e$2.2 million\u003c\/strong\u003e for the three months ended March 31, 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the advantage is only realized if the focused effort succeeds faster than a diversified approach.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMarch 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorking Capital\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMarch 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Operating Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThree months ended June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThree months ended June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.39M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecember 06, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e16\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCurrent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFinancing secured: \u003cstrong\u003e$15.0 million\u003c\/strong\u003e in gross proceeds via private placement.\u003c\/li\u003e\n\u003cli\u003ePhase 2 topline results expected: \u003cstrong\u003e12 to 18 months\u003c\/strong\u003e following FDA clearance.\u003c\/li\u003e\n\u003cli\u003eEPS (TTM): \u003cstrong\u003e-1.25\u003c\/strong\u003e USD.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents: \u003cstrong\u003e$1.0 million\u003c\/strong\u003e as of September 30, 2024.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses for six months ended March 31, 2025: \u003cstrong\u003e$1.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516155912341,"sku":"edsa-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/edsa-vrio-analysis.png?v=1740168956","url":"https:\/\/dcf-model.com\/pt\/products\/edsa-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}